![Robert Petit](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Robert Petit
Teknisk/Vetenskaplig/F&U Direktör på
OS THERAPIES INCORPORATED
Förmögenhet: 338 000 $ per 2026-08-31
Profil
Robert G.
Petit is currently Senior VP & Head-Early Clinical Development at Orionis Biosciences, Inc. since 2022.
He is Chief Medical & Scientific Officer at OS Therapies, Inc. since 2019.
He is Principal at RGP Biotech, LLC since 2019.
Formerly, Dr. Petit was Director-Medical Strategy at Bristol Myers Squibb Co. from 2005 to 2010.
He was Vice President-Clinical Development at MGI PHARMA, Inc. and Aesgen, Inc. He was Chief Scientific Officer & Executive VP at Advaxis, Inc. from 2010 to 2019.
He was Chief Scientific Officer at CTx Operations, Inc. and Carisma Therapeutics, Inc. in 2019.
Dr. Petit completed undergraduate studies at Indiana State University and earned a doctorate from The Ohio State University.
Kända innehav i offentliga företag
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2026-07-21 | 200 000 ( 0,43 % ) | 338 000 $ | 2026-08-31 |
Aktiva positioner av Robert Petit
| Företag | Position | Start |
|---|---|---|
| OS THERAPIES INCORPORATED | Teknisk/Vetenskaplig/F&U Direktör | 2019-09-01 |
RGP Biotech, LLC | Företagsledare/Principal | 2019-06-01 |
Orionis Biosciences, Inc.
 Orionis Biosciences, Inc. Packaged SoftwareTechnology Services Offers protein interaction platform with direct applications in the discovery of new therapeutics | Företagsledare/Principal | 2022-03-01 |
Tidigare kända positioner av Robert Petit
| Företag | Position | Slut |
|---|---|---|
CTx Operations, Inc.
 CTx Operations, Inc. BiotechnologyHealth Technology Develops macrophage-based immunotherapeutic for treatment of cancer | Teknisk/Vetenskaplig/F&U Direktör | 2019-12-01 |
| CARISMA THERAPEUTICS, INC. | Teknisk/Vetenskaplig/F&U Direktör | 2019-12-01 |
| BRISTOL-MYERS SQUIBB COMPANY | Företagsledare/Principal | 2010-01-01 |
Aesgen, Inc.
 Aesgen, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Företagsledare/Principal | - |
MGI PHARMA, Inc.
 MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology Develops. manufactures & markets pharmaceutical and medical products for therapeutic markets | Företagsledare/Principal | - |
Robert Petits utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
83
Första gradens relationer
11
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 11 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
MGI PHARMA, Inc.
MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology Develops. manufactures & markets pharmaceutical and medical products for therapeutic markets | Health Technology |
Aesgen, Inc.
Aesgen, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Indiana State University
 Indiana State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Advaxis, Inc.
 Advaxis, Inc. Pharmaceuticals: MajorHealth Technology Develops immunotherapies for cancer and infectious diseases | Health Technology |
The Ohio State University
 The Ohio State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Orionis Biosciences, Inc.
Orionis Biosciences, Inc. Packaged SoftwareTechnology Services Offers protein interaction platform with direct applications in the discovery of new therapeutics | Technology Services |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology Develops macrophage-based immunotherapeutic for treatment of cancer | Health Technology |
OS Therapies, Inc.
 OS Therapies, Inc. BiotechnologyHealth Technology Operates as a clinical stage therapeutic company engages in development and commercialization of treatments for osteosarcoma | Health Technology |
Carisma Therapeutics, Inc.
 Carisma Therapeutics, Inc. BiotechnologyHealth Technology Develops novel chimeric antigen receptor macrophage and CAR-monocyte technology treatment of non-muscle invasive bladder cancer | Health Technology |
RGP Biotech, LLC |
